mRNA-Based Therapeutics Summit Europe - Digital Event

Successfully Design and Develop Next-Generation of mRNA- Based Vaccines and Therapeutics with Improved Specificity, Delivery and Efficacy for Immuno-Oncology, Infectious Diseases and Beyond

Datum: 25. - 27.01.2022
Uhrzeit: 08:30 Uhr - 16:00 Uhr

Built with biopharmaceutical industry insights, this in-person conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines and therapeutics with improved specificity, delivery and efficacy for immuno-oncology, infectious diseases and beyond.

With 20+ pioneering large pharma, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide, hear how they address the major challenges facing the industry.

Optimise the Efficacy, Cell- and Tissue- Specificity and Translatability of Your mRNA- Based Pipeline
With the limitless opportunity of mRNA- based Therapeutics across different modalities, consider the challenges of efficacy and improve cell- and tissue- specificity with expert insights from Professor Drew Weissman, Strand Therapeutics and Chalmers University of Technology

Explore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases
From immune-oncology to rare and autoimmune diseases, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna, BioNTech and Ethris

Navigate New and Emerging Delivery Technologies for mRNA- Based Therapeutics
Take yourself to the forefront of mRNA delivery system development, from structure through to administration with insights from BioNTech, Johnson and Johnson and Med Therapeutics

Strategise Your Scalable and Global mRNA-Based Vaccine Development
With the global outreach of mRNA- based vaccines, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi, Ziphius Vaccines and Arcturus Therapeutics

Tune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines
With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement, hear from companies like Strand Therapeutics, Turn Biotechnologies and Orna Therapeutics on the emerging strategies that will enable innovation in the field

Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!


Conference Only - Drug Developer: EUR 1999.0,
Conference + 1 Workshop - Drug Developer: EUR 2348.0,
Conference + 2 Workshops - Drug Developer: EUR 2697.0,
Conference Only - Standard Pricing: EUR 2299.0,
Conference + 1 Workshop - Standard Pricing: EUR 2648.0,
Conference + 2 Workshops - Standard Pricing: EUR 2997.0,
Conference Only - Academic: EUR 1699.0,
Conference + 1 Workshop - Academic: EUR 1998.0,
Conference + 2 Workshops - Academic: EUR 2297.0

Speakers: Amar Deep Sharma Group Leader Hannover Medical School, Andreas Kuhn Senior VP - RNA Biochemistry and Manufacturing BioNTech, Arun Kumar Preclinical Vaccines Development Lead Coalition for Epidemic Preparedness Innovations (CEPI), Carsten Rudolph CEO Ethris, Christian Hotz Director - In Situ Therapy BioNTech, Danilo Casimiro CSO Sanofi Pasteur, Dariush Mohammadyani Senior Scientist Johnson and Johnson, Drew Weissman Professor - Vaccine Research University of Pennsylvania, Perelman School of Medicine, Dushyant Varshney Executive VP and CTO Arcturus Therapeutics, Elaine Peters Director - Analytical Lead Genentech, Heinrich Haas VP - Formulation and Delivery BioNTech, Jacob Becraft Co-Founder and CEO Strand Therapeutics, Jaspreet Khurana Director - Platform and Discovery Strand Therapeutics, Jay Sarkar Co-Founder Turn Biotechnologies, Lucia Lapazio Group Lead - mRNA Sanofi, Marcus Wilhelmsson Professor Chalmers University of Technology, Mathieu Ghadanfar CMO Ziphius Vaccines, Michiel Lodder CEO 20Med Therapeutics, Patrick Finn Senior Director - Rare Diseases Moderna, Roland Pach Global Expert Cell and Gene Therapy Analytics Roche Pharmaceuticals, Steve Pascolo Principal Investigator University Hospital of Zurich, Thomas Langenickel CMO Ethris, Tom Barnes CEO Orna Therapeutics


Medizinische Informatik, Pharmakologie und Toxikologie


Hanson Wade
Zur Adresse


DE 00000 Online
Zur Anfahrt


Hotels in der Nähe des Veranstaltungsortes anzeigen

Diese Veranstaltung via E-Mail weiterempfehlen


Hanson Wade
52 Grosvenor Gardens
GB SW1W 0AU London
Telefon: +1 617 455 4188


Katie Jacobs
52 Grosvenor Gardens
GB SW1W 0AU London
Telefon: +16174554188



Bisher leider keine Daten vorhanden


DE 00000 Online

Größere Kartenansicht

Weitere Informationen

Turnus: keine Wiederholung

Kosten: EUR 2997,00

mrna, mrnatherapeutics, infectiousdiseases, mrnavaccines

Wissenschaftliche Leitung:
Katie Jacobs